AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
- Details
The new OCT angiography system is the first to allow quick, noninvasive measurement of retinal blood flow density.
Read more: FDA approves OCT angiography for blood flow measurement
- Details
This analysis of data from the CATT and IVAN trials found no evidence that VEGFR2 genotypes affect response to anti-VEGF therapy in patients with wet AMD, contrary to a previous report.
Read more: Genes don’t affect response to anti-VEGF treatment
- Details
Alcon has entered the MIGS market with its acquisition of Transcend Medical and its micro-stent CyPass.
- Details
Aerie Pharmaceuticals announced positive 12-month interim safety results for Rhopressa, a once-daily eye drop for patients with glaucoma or ocular hypertension.
- Details
The ArcScan Insight 100 can image and measure anterior chamber depth, angle-to-angle width, individual corneal layers and sulcus-to-sulcus width, all with micron level precision.
- Details
Six-month results from this phase 2 randomized study shows that the anti-seizure drug phenytoin protects against retinal nerve fiber layer loss in acute optic neuritis.
Read more: Anti-seizure drug appears neuroprotective in acute optic neuritis